Objective:This paper provides a brief overview of the epidemiology of colorectal cancer in China and around the world, and discusses how to prevent colorectal cancer to reduce its disease burden.Method:Using the official database of GLOBOCAN 2020, the China Cancer Registry Annual Report compiled by the National Cancer Center, and data from CONCORD-3.Data management was performed by Microsoft Excel 2016 and R 4.2.1 Relevant graphs were generated using the ggplot2 package for result visualization.Result:An estimated 1 931 590 people were diagnosed with colorectal cancer worldwide in 2020 with an age-standardized incidence rate of 19.5 per 100 000. There were about 935 173 deaths caused by colorectal cancer internationally, with an age-standardized mortality rate of 9.0 per 100 000. Overall, colorectal cancer was the fourth most commonly diagnosed cancer and the third leading cause of cancer-related death worldwide in 2020. In China, the age-standardized incidence rate and mortality rate of colorectal cancer was 17.3 per 100 000 and 7.8 per 100 000, respectively. Gender differences in trends were observed, with a decreasing trend in incidence and mortality among females and an increasing trend in incidence and mortality among males. The primary risk factors for colorectal cancer include age, genetic factors, gastrointestinal disorders, dietary habits, and lifestyle et al.Conclusions:Colorectal cancer poses a significant burden globally and in China. The occurrence of colorectal cancer is closely related to physiology, genetics, behavioral habits, lifestyle, and disease factors. To better control the colorectal cancer burden with the lowest cost, specific measures should be taken to reduce exposure to established risk factors. By combining the disease prevention and control strategies of tertiary prevention in China with the characteristic factors of colorectal cancer, the incidence and mortality of colorectal cancer may be effectively controlled.

Lung cancer remains one of the leading cause of global cancer-related mortality, posing a significant burden of disease. Tobacco exposure stands as the foremost risk factor for lung cancer. Since the 1960, global efforts have gradually been implemented to control tobacco exposure, consequently reducing tobacco exposure levels within populations. This shift in exposure levels may have altered the epidemiological characteristics of lung cancer globally. This study aims to describe global lung cancer incidence data across five dimensions: age, gender, region, stage at diagnosis, and survival status, using global cancer registry data and relevant research findings. The objective is to elucidate the current epidemiological features of lung cancer worldwide, providing a scientific basis for lung cancer prevention and control. Furthermore, this study offers corresponding measures and recommendations for lung cancer prevention and control, aligning with the three-tiered cancer prevention strategy. Findings indicate that the incidence and mortality burden of lung cancer is significantly higher among the elderly population (aged 65 years and above) compared to the working-age population (aged 15-64 years). The aged-standardized incidence rate of lung cancer remains higher in males than in females, but the overall aged-standardized incidence rate of lung cancer in males shows a declining trend, while that in females shows an increasing trend. Regions with high and very high human development index (HDI) exhibit a substantially higher incidence and mortality burden of lung cancer compared to regions with low and very low HDI. Japan ranks highest in the diagnosis of stage Ⅰ lung cancer, with a diagnosis rate of 38.6%. Its age-standardized 5-year net survival rate is relatively high at 32.9%. Despite improvements in the survival status of lung cancer in certain countries like China and Japan, the overall prognosis for lung cancer remains pessimistic. Given the current epidemiological characteristics of lung cancer, reinforcing tobacco control measures and reducing female-specific lung cancer risk factors stand as significant goals for primary prevention. Promoting low-dose computed tomography screening for high-risk population, minimizing false-positive rates in lung cancer screening, and promoting medical system reforms and standardized treatment constitute principal measures for secondary and tertiary lung cancer prevention, respectively.

Objective:To analyze the incidence, mortality, and survival status and trends of lung cancer in China.Methods:The data of incidence, mortality, disability-adjusted life year (DALY), and survival status and trends of lung cancer in China were collected from GLOBOCAN 2020, Global Burden of Disease Study in 2019 (GBD2019) databases, and the CONCORD-3 project report. Joinpoint 5.0 software was used to analyze the age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR) of lung cancer in China from 1990 to 2019. Data management was conducted by using Excel 2016, and relevant graphical representations were generated using the ggplot2 package in software R 4.2.1.Results:In 2020, a total of 815 563 lung cancer cases were newly reported in China with the ASIR of 34.8/100 000, in which 539 181 cases were reported in men, with the ASIR of 47.8/100 000, and 276 382 cases were reported in women, with the ASIR of 22.8/100 000. A total of 714 699 lung cancer deaths were reported in 2020, with the ASMR of 30.2/100 000. Among these deaths, there were 471 546 deaths in men with the ASMR of 41.8/100 000, and 243 153 deaths in women with the ASMR of 19.7/100 000. From 1990 to 2019, the ASIR and ASMR of lung cancer in both men and women showed increasing trends ( P<0.05). However, from 2010 to 2019, the ASIR and ASMR of lung cancer in men showed decreasing trends, with annual percent of change (APC) of -0.17% (95% CI: -0.24% - -0.09%) and -0.69% (95% CI: -0.79% - -0.59%), respectively. The ASIR and ASMR of lung cancer in women showed increasing trends from 2016 to 2019, with APC of 3.33% (95% CI: 2.73% - 3.88%) and 2.61% (95% CI: 1.99% - 3.28%), respectively. The five-year net survival rate for lung cancer was 19.8% in China (95% CI:19.4% - 20.2%) from 2010 to 2014. Conclusions:The morbidity and mortality of lung cancer in China remain at high levels, the prognosis of lung cancer was poor, and the disease burden of lung cancer would become more serious in the context of population aging, so three-level prevention of lung cancer should be implemented to address this problem. In addition, attention should be paid to the increasing trends of ASIR and ASMR of lung cancer in women in recent years. Further investigation of risk factors and targeted prevention are needed to curb the rising trend in the incidence of lung cancer in women.

Background::Lung cancer is the most common cancer and a leading cause of cancer-related deaths globally. The aim of this study was to evaluate the incidence and mortality of lung cancer worldwide in 2022 and to project the number of new cases and deaths due to lung cancer in China and the United States in 2050.Methods::In this study, data from the GLOBCAN 2022 database were used to analyze lung cancer incidence and mortality. The current status of lung cancer incidence and deaths was described by country/region, sex, age, and the human development index (HDI), and future lung cancer incidence and deaths in China and the United States were projected for 2050.Results::Globally, an estimated 2,480,675 new lung cancer cases and 1,817,469 lung cancer-related deaths occurred in 2022, with age-standardized incidence rates (ASIRs) and age-standardized mortality rates (ASMRs) of 23.6/100,000 and 16.8/100,000, respectively. In China, the ASIR and ASMR for male lung cancer patients were approximately 1.7 times and 2.7 times greater than those for female lung cancer patients, respectively. The ASIR and ASMR in high-HDI countries were approximately 8.5 times and 6.5 times those in low-HDI countries, respectively. It is estimated that in 2050, there will be approximately 1120 thousand new cases and 960 thousand deaths among Chinese men, 680 thousand new cases and 450 thousand deaths among Chinese women, approximately 170 thousand new cases and 110 thousand deaths among American men, and 160 thousand new cases and 90 thousand deaths among American women.Conclusions::There are significant differences in the incidence and mortality of lung cancer among different regions and sexes. Therefore, sex factors need to be considered in the prevention, screening, and treatment strategies of lung cancer, and the implementation of tertiary prevention measures for lung cancer, especially primary and secondary prevention, needs to be actively promoted.

Objective:To investigate the protective effect of gastrodin combined with celecoxib on cartilage injury in rats with knee osteoarthritis through Toll-like receptor 4 (TLR4)/nuclear factor-κB (NF-κB) signaling pathway.Methods:Knee osteoarthritis rat models were established by the modified Hulth method. According to the random number table method, rat models were randomly divided into the model group, the gastrodin group, the celecoxib group, and combined group with 10 rats in each group. An additional 10 healthy rats were selected and served as the control group. The rats in the gastrodin group received 50 mg/kg gastrodin by intraperitoneal injection. The rats in the celecoxib group received 4 mg/kg celecoxib by gavage. In the combined group, the rats received 50 mg/kg gastrodin by intraperitoneal injection, followed by 4 mg/kg celecoxib by gavage. Rats in both the control group and the model group received intraperitoneal injections and gavage of an equal volume of normal saline, which were administered once a day for 21 d. The symptoms of joint pain, the degree of joint swelling, the width of the knee joint, the joint function, and the cartilage thickness of the rats in all groups were compared. The expression level of proinflammatory factors, including interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-17 (IL-17), and tumor necrosis factor-α (TNF-α), in cartilage was determined by enzyme-linked immunosorbent assay (ELISA). The relative expression levels of TLR4 and NF-κB proteins and genes in cartilage were detected by Western blotting and real-time reverse transcription-PCR (RT-qPCR), respectively.Results:The mechanical pain threshold [(19.77±2.05) g] and thermal pain threshold [(10.06±1.54) s] in the combined group were higher than those in the model, gastrodin, and celecoxib groups [(5.27±1.23), (11.27±1.55), and (12.85±1.62) g for mechanical pain threshold, and (4.26±0.84), (7.21±1.31), (7.36±1.15) s for thermal pain threshold], respectively, and the differences were statistically significant (all P<0.05). The degree of joint swelling [(8.23±1.05)%], knee joint width [(5.19±0.23) mm], and gait score [(0.56±0.22) points] in the combined group were all lower than those in the model, gastrodin, and celecoxib groups [(38.26±6.77)%, (17.76±2.18)%, and (17.23±2.44)% for joint swelling degree, (9.86±1.16), (6.43±0.54), and (6.23±0.78) mm for knee joint width, and (2.25±0.47), (1.26±0.23), and (1.25±0.14) points for gait score], respectively, and the differences were statistically significant (all P<0.05). The levels of IL-1β [(53.37±10.26) pg/ml], IL-6 [(51.26±6.22) pg/ml], IL-17 [(136.33±8.67) pg/ml], and TNF-α [(62.36±12.03) pg/ml] in the cartilage tissue of rats in the combined group were all lower than those in the model, gastrodin, and celecoxib groups [IL-1β: (112.33±18.56), (76.55±12.03), (72.69±14.88) pg/ml; IL-6: (90.33±12.06), (69.23±8.09), (65.42±7.01) pg/ml; IL-17: (215.66±20.22), (165.33±14.69), (160.36±15.55) pg/ml; TNF-α: (138.09±18.26), (89.66±15.36), (84.03±14.77) pg/ml], respectively, and the differences were statistically significant (all P<0.05). Compared with the model group, the cartilage thickness of rats in the gastrodin, celecoxib, and combined groups [(945.86±63.87), (962.75±129.14), (1 410.48±60.42) μm] were increased, and the differences were statistically significant (all P<0.05). The relative expression levels of TLR4 and NF-κB proteins [(2.13±0.88), (2.01±0.35)] and mRNAs [(1.48±0.11), (1.73±0.12)] in the cartilage tissue of rats in the combined group were all lower than those in the model group [TLR4, NF-κB proteins: (5.26±0.95), (4.32±0.71); mRNAs: (4.37±0.43), (5.27±0.48)], the gastrodin group [TLR4, NF-κB proteins: (3.22±0.75), (3.16±0.33); mRNAs: (2.53±0.21), (3.52±0.22)], and the celecoxib group [TLR4, NF-κB proteins: (3.26±0.61), (3.19±0.30); mRNAs: (2.55±0.24), (3.55±0.31)], and the differences were statistically significant (all P<0.05). Conclusions:Gastrodin combined with celecoxib can inhibit the symptoms of joint pain and inflammation in rats with knee osteoarthritis by inhibiting the activation of TLR4/NF-κB signaling, and alleviate the cartilage injury.

Objective To analyze the impacts of bureaucracy management at tertiary public hospitals in Beijing on exchange modes and trust between doctors and patients, using both the bureaucracy theory and trust theory. To study the role of such management as an organizational structure for hospital operation and service, in the transition of doctor-patient trust from traditional special trust to a universal trust based on bureaucracy structure and specialized job division. Methods The purpose sampling method was used to select 94 hospital administrators, medical staff, and patients from six tertiary hospitals for a field survey. Results Bureaucracy at public tertiary hospitals keeps improving, and its systematic and refined organizational structure is changing the exchanges between doctors and patients, earmarking universal trust of the fundamental type of doctor-patient trust, aided by special trust. Rules and regulations of bureaucracy normalize medical services, and specialization enables medical workers in their clinical work against difficult and severe diseases, winning both reputation and patient trust as well. However, the specialized, professional and dehumanized characteristic of bureaucracy tend to encourage doctors to attend to diseases than patients, and separate links in medical services to decrease doctor-patient trust in the meantime. Conclusions Bureaucracy is a necessary organizational form of urban public hospitals, but it should strengthen their humanity feature and improve their communication with patients with rules and regulations. At the same time, with the use of integrated medical mode in clinical practice, bureaucracy could be improved to benefit patients and enhance trust of patients.